Creating a new formulation to improve flu vaccines
Official title: DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines
Funded at Molecular Express, INC. · NIH-10933265 · Data updated 2026-11-12
This study is testing a new type of flu vaccine that uses special ingredients to boost your immune response, aiming to provide better protection against the flu, especially during flu season.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Express, INC. NIH-funded |
| Lab location | 1 site (Rancho Dominguez, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2025 |
| Funding year | 2023 |
| Award (this year) | $599,925 |
| NIH project number | 75N93023C00033-0-9999-1 |
| Project ID | NIH-10933265 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at higher risk for influenza, such as the elderly, young children, or those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for influenza or those who have already received a flu vaccine may not benefit from this research.
What this research studies
This research focuses on developing a new formulation for flu vaccines that combines signal modifiers with a specific lipid to enhance the immune response. Using a proprietary liposomal system called VesiVax, the researchers aim to create a more effective vaccine that can better protect against the influenza virus. Patients may benefit from improved vaccine efficacy, leading to better protection during flu seasons. The research involves laboratory work primarily with animal models to test the new vaccine formulation.
Why it matters
Potential benefit: If successful, this research could lead to more effective flu vaccines that provide better protection against influenza.
How similar studies have gone: Other research has shown promise in enhancing vaccine efficacy through similar approaches, indicating potential for success in this area.
Where this research is happening
-
Molecular Express, INC.
Rancho Dominguez, United States Active
Researchers
- Principal investigator: Onho, Sam — Molecular Express, INC.
- Study coordinator: Onho, Sam
Related research
Other NIH-funded projects on the same topics.
-
Developing a new vaccine adjuvant to enhance immune response against gonorrhea and aspergillosis
This study is working on a new helper ingredient for vaccines called ME-M-006, which aims to make vaccines more effective against infections like gonorrhea and a type of fungus, so that people can have better protection when they get vaccinated.
-
Creating new HIV vaccines using advanced delivery systems
This study is working on new HIV vaccines that use tiny particles to help your immune system recognize and fight the virus better, so you could get a stronger and more effective vaccine in the future.
-
Developing a synthetic lung surfactant for preterm infants
This study is testing a new treatment called ME-1001, a synthetic lung surfactant, to help preterm babies with respiratory distress syndrome breathe better and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.